(Updated with corrected FDA approval decision date for Avanir Pharmaceuticals, which is Oct. 30, not Oct. 27, as previously reported.)
BOSTON (TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. This FDA regulatory calendar is an update to the FDA approval calendar posted on April 7 and includes information on four new stocks with approval decision dates scheduled through the end of October. The 14 stocks are listed in chronological order, starting with the earliest FDA approval decision date.
Questcor Pharmaceuticals (QCOR)
Drug/indication: Acthar for infantile spasmsApproval decision date: June 11 An FDA advisory panel said Acthar was safe and effective as a treatment for infant spasms at a meeting on May 6. Glaxo's Radical Heart Drug (Forbes)